7210 Wareham Drive, Tampa, FL 33647
August 8, 2024 A Financial Times article reported that… “Eli Lilly chief executive David Ricks said the better than expected sales in its most recent quarter were driven by the GLP-1 medicines as the drugmaker “advanced our manufacturing expansion agenda” to meet the huge demand for the medicines. Increased pricing power for Mounjaro also boosted […]
Eli Lilly Posts Strong Weight Loss Drug Sales Read More »
August 5, 2024 Wellness company Medifast (NYSE:MED) fell short of analysts’ expectations. Management said that: “We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded
Medifast Reports Q2 Results Read More »
August 1, 2024 In August, Certificates of Analysis on the compounded GLP-1 medications available through Hims & Hers will be accessible to customers, in an effort to introduce a higher level of transparency that helps our customers understand what is in the medications they receive, as well as how to understand the high quality standards
Hims & Hers To Offer Certificates of Analysis for Compounded GLP-1s Read More »
August 1, 2024 Management reported that: “WeightWatchers has the right strategy to return the business to growth. With a rapidly changing landscape, we are taking decisive actions to navigate through this environment and completely reimagining how we operate,” said Sima Sistani, the Company’s CEO. “We are executing a significant streamlining of our operational structure, to
Weight Watchers Reports Q2 Results Read More »
July 11, 2024 An article by Endpoints.com cited a study that found that only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. Prime, which is owned by a group of Blue Cross Blue Shield
Nearly all patients quit weight loss shots within two years, study finds Read More »
June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the
Employers and Insurers Push Back on GLP-1 Drugs Coverage Read More »
May 22, 2024 A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association. The study was conducted by Blue Health Intelligence and is based on national pharmacy and medical claims data from
Most weight loss drug users quit before seeing benefits Read More »
May 20, 2024 Medifast today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA’s new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program. View the full release here: https://www.businesswire.com/news/home/20240520770526/en/ This will be an investment of up to $30 million in company-led marketing efforts. Medifast is committed
Medifast To Launch National Marketing Campaign Read More »
May 9, 2024 Novo Nordisk is beginning work on a follow-up weight loss medicine that would last longer and could be manufactured more easily. On Thursday, the company unveiled a research project aimed at adding up to two more obesity treatments to its large pipeline, which already includes a long list of experimental obesity drugs
Novo Nordisk Working On Even Better Weight Loss Drugs Read More »
May 9, 2024 John LaRosa, Marketdata’s Research Director and founder, was recently interviewed by Kimberly Adams at Marketplace, a business and economic program, along with several others, about how the weight loss market is changing currently, being affected by the hugely popular GLP-1 weight loss medications. Here’s the interview, on audio. Click this link to
How GLP-1 Drugs Are Changing The Weight Loss Market – Podcast Read More »